This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Prasco Expands Authorized Generic Product Line With Vancocin® HCl Capsules

Stocks in this article: VPHM





CINCINNATI, April 11, 2012 /PRNewswire/ --  Prasco Laboratories announced today it will market the Authorized Generic version of Vancocin ® HCl Capsules (vancomycin hydrochloride capsules, USP) in 125 mg, and 250 mg strengths in the U.S. under the Prasco label pursuant to its distribution and supply agreement with ViroPharma Incorporated (NASDAQ: VPHM).  Prasco intends to launch immediately.

"We are pleased to have established this relationship with ViroPharma," said Prasco Chief Executive Officer, Chris Arington.   "Consumers and pharmacists will have as one of their prescription drug choices an Authorized Generic product that provides the identical product, quality, reliability and experience as the brand."

"Prasco is the industry leader in Authorized Generics and we are pleased to have partnered with them on this project," commented Dan Soland, ViroPharma's Chief Operating Officer.  "Through this partnership, patients suffering from dangerous C. difficile infections will now have access to a generic formulation of Vancocin that is identical to the brand, and proven through decades of use to be a high quality treatment for this potentially deadly disease."

Vancocin ® HCl is a registered trademark of ViroPharma Incorporated.

About Vancomycin Hydrochloride Capsules

Vancomycin Hydrochloride Capsules are indicated for the treatment of C. difficile-associated diarrhea (CDAD).  Vancomycin Hydrochloride Capsules are also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).  Vancomycin Hydrochloride Capsules are contraindicated in patients who have experienced a hypersensitivity to vancomycin.  Vancomycin Hydrochloride Capsules must be given orally for treatment of staphylococcal enterocolitis and CDAD.  Orally administered Vancomycin Hydrochloride Capsules are not effective for other types of infections.  Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of Vancomycin Hydrochloride Capsules for active CDAD.  Monitoring of serum concentrations may be appropriate in some instances. 

Nephrotoxicity has occurred following oral Vancomycin Hydrochloride Capsules therapy and can occur either during or after completion of therapy. The risk is increased in geriatric patients.  Monitor renal function.  Ototoxicity has occurred in patients receiving Vancomycin Hydrochloride Capsules.  Assessment of auditory function may be appropriate in some instances.  Prescribing Vancomycin Hydrochloride Capsules in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.  In clinical trials, the most common adverse reactions (greater than or equal to 10 percent) were nausea (17 percent), abdominal pain (15 percent) , and hypokalemia (13 percent).  Patients over 65 years of age may take longer to respond to therapy compared to patients less than 65 years of age.  Clinicians should be aware of the importance of appropriate duration of Vancomycin Hydrochloride Capsules treatment in patients over 65 years of age and not discontinue or switch to alternative treatment prematurely. 

For Vancomycin Hydrochloride Capsules prescribing information, please visit: http://www.prasco.com/downloads/Product%20PIs/66993-211-19.pdf



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs